Endonovo at the Intersection of Stem Cells and Biologics for Next Generation Therapeutics - SECFilings.com

Stock Information for Endonovo Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Endonovo Therapeutics Inc

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Endonovo's SofPulse® Secures Taiwan FDA Approval
Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
Endonovo Pending Agreement to Develop Telehealth Division

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.